Michigan is currently home to 2199 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Innoventric Trilliumâ„¢ Stent Graft Early Feasibility Study (EFS)
Recruiting
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trilliumâ„¢ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2025
Locations: Ascension St. John, Detroit, Michigan
Conditions: Tricuspid Regurgitation, Tricuspid Regurgitation Functional
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Detroit, Michigan
Conditions: Pulmonary Sarcoidosis
Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial
Recruiting
This trial is being completed to compare two commonly used options to treat pain after surgery. Participants that undergo gallbladder removal, hernia repair, and breast lump removal will be eligible to enroll. Eligible participants will be randomized to 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) plus acetaminophen or low dose opioids plus acetaminophen). It is anticipated that the NSAID group will have superior clinical outcomes and fewer side effects when comp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Surgery, Pain, Postoperative
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Recruiting
The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Mantle Cell Lymphoma
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
Recruiting
This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30 mg/kg.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
Conditions: Advanced Solid Tumor
Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)
Recruiting
This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Endo Site 16, Grand Rapids, Michigan
Conditions: Plantar Fibromatosis, Ledderhose Disease
Real World Registry for Use of the Ion Endoluminal System
Recruiting
The primary objective of this study is to evaluate the performance of the Ion Endoluminal System with real-world use for pulmonary lesion localization or biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Advanced Solid Tumor
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 243438, Ann Arbor, Michigan
Conditions: Relapsed/Refractory Multiple Myeloma
Preventing Relapse of Problem Behavior Through Behavioral Economics: A Translational Analysis
Recruiting
The goal of this clinical trial is to compare a novel tactic for mitigating reinstatement compared to the current standard of care approach using a translational-treatment model. The main questions it aims to answer are: 1. how well does progressive ratio training mitigate response-dependent reinstatement compared to the standard of care approach? 2. how well does progressive ratio training mitigate response-independent reinstatement compared to the standard of care approach?
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
02/28/2025
Locations: Oakland University, Rochester, Michigan
Conditions: Problem Behavior
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients with Vitiligo
Recruiting
The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/28/2025
Locations: CLINUVEL site, Detroit, Michigan
Conditions: Vitiligo
Project 4: ACHIEVE PATHFINDER
Recruiting
ACHIEVE-P4: PATHFINDER is a randomized, blinded clinical trial of portable air cleaners (PAC) provided at the time of hospital discharge to Heart Failure (HF) patients. It will be carried out at Henry Ford Hospitals. This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health Inequities by Early PreVEntion in the GREAT LakEs Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality. The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Heart Failure